Estimated date of death.Estimated date of event.The udi is unknown because the part number and lot number were not provided.Estimated date of implant.The device was not returned for evaluation.The reported patient effect of death is listed in the xience v and xience nano everolimus eluting coronary stent systems instructions for use as a known patient effect of coronary procedures.A review of the lot history record of the reported lot could not be conducted because the part and lot number were not provided.A conclusive cause for the reported death and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.The adverse patient effects mentioned are being filed in a separate medwatch report number.Article: comparison of ultrathin, bioresorbable-polymer sirolimus-eluting stents and thin, durable- polymer everolimus-eluting stents in calcified or small vessel lesions.
|
It was reported through a research article identifying that xience stents may be related to the following: death, myocardial infarction, ischemia, stent-thrombosis, rehospitalization and revascularization.This article summarizes clinical outcomes of 784 patients that were treated with xience stents.Specific patient information is documented as unknown.Details are listed in the article, titled "comparison of ultrathin, bioresorbable-polymer sirolimus-eluting stents and thin, durable- polymer everolimus-eluting stents in calcified or small vessel lesions.".
|